GlassScriptPhysician profile
Carrie Wasserman
NPI 1255567285
$20,005.66
in general payments reported to CMS, 2019-2025
42 companies · $306 in 2025
The $306 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $705 · 2021: $408 · 2022: $4,267 · 2023: $1,024 · 2024: $59.29 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823 · Consulting Fee: $545 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.23 |
| Consulting Fee | $545.00 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,094.10 | 2019-2025 | Tagrisso, Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $5,894.68 | 2019-2023 | |
| Janssen Scientific Affairs, LLC | $1,302.50 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $547.84 | 2019-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $300.90 | 2019-2025 | |
| Pfizer INC. | $230.39 | 2019-2023 | |
| Genzyme Corporation | $205.35 | 2022-2023 | |
| Daiichi Sankyo INC. | $182.06 | 2019-2023 | Enhertu |
| Janssen Biotech, INC. | $176.77 | 2019-2023 | Tecvayli |
| Seagen INC. | $176.04 | 2021-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $162.94 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Alexion Pharmaceuticals, INC. | $155.83 | 2019 | |
| Allergan, INC. | $134.57 | 2020 | |
| Eisai INC. | $111.71 | 2020-2022 | |
| Genentech USA, INC. | $108.57 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.